(redirected from Adjuvant Endocrine Therapy)
Category filter:
AETAetna, Inc.
AETAdjuvant Endocrine Therapy (women's health)
AETAustralian Eastern Time (time zone)
AETAfter Extra Time
AETAircraft Electronics Technician (National Center for Aerospace and Transportation Technologies)
AETAdvanced Energy Technology (various locations)
AETAcer Empowering Technology
AETAide à l'Enfance Tibétaine (French: Help Tibetan Children)
AETAetatis (Latin: Of Age)
AETActual Evapotranspiration
AETAnesthesia End Time
AETApplied Extrusion Technologies, Inc.
AETAtelier Européen de la Traduction (French: European Translation Workshop)
AETAdvanced Evasion Technique
AETAlliance for Environmental Technology
AETAfrica Educational Trust (London, UK)
AETAssistant English Teacher
AETApparent Effects Threshold
AETApplication Entity Title
AETAssociation Européenne de Terminologie (French: European Association for Terminology; Brussels, Belgium)
AETAbility Engineering Technology (South Holland, IL)
AETAffective Events Theory
AETAlternate Energy Technologies, LLC (Jacksonville, FL)
AETAssociation of Electrical Technologists (Purdue University; Indiana)
AETAdvanced Engine Technology (Canada)
AETAvionics Electrical Technician (US Coast Guard)
AETAtrial Ectopic Tachycardia
AETAminoethylisothiouronium (radiation protection agent)
AETAmerican Engineering Testing, Inc
AETAntimicrobial Effectiveness Testing
AETApports Energétiques Totaux (French: Total Energy Intake)
AETAdvanced Extraction Technologies, Inc
AETAnnual Ethics Training
AETAllakaket, AK, USA (Airport Code)
AETActual Evapo-Transpiration
AETArmy Extension Training
AETAerospace Engineering Technician
AETAcoustic Emission Technique
AETAircrew Egress Trainer
AETAssociated Environmental Trainer (NETA)
AETAutomatic Equipment Test (Sprint)
AETAscent Ephemeris Tape
AETAllowable Elapsed Time
AETAsynchronous Encodings in Tandem
AETAlgorithm Evaluation and Test
AETAeromedical Evacuation Technician
AETAccelerated Environmental Test
AETAerosurface End-to-end Test
AETAction Extreme Team (USA network show)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
All of the patients received adjuvant endocrine therapy.
Adjuvant endocrine therapy (AET), such as tamoxifen, is often recommended for postmenopausal women for as long as 10 years after completion of breast cancer treatment as a means to limit the risk of cancer recurrence.
Additionally, in MONARCH 3, the exploratory subpopulation treatment effect pattern plot, or STEPP, analysis of treatment-free interval, or how quickly the cancer returned after the completion of adjuvant endocrine therapy, showed those whose cancer returned quickly after the conclusion of adjuvant endocrine therapy derived larger benefit from the addition of Verzenio compared to endocrine therapy alone.
The recently reported American Society of Clinical Oncology Clinical Practice Guideline Focused Update: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer endorsed multi-gene tests, like BCI, to aid in decisions regarding extended adjuvant endocrine therapy for patients with early stage HR+ breast cancer.
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
MONDAY, June 4, 2018 (HealthDay News) -- For women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer with a midrange 21-gene recurrence score, adjuvant endocrine therapy is noninferior to chemoendocrine therapy, according to a study published online June 3 in the New England Journal of Medicine.
Adjuvant endocrine therapy, also known as hormone therapy, is a treatment used by breast cancer patients to prevent the cancer from returning after surgery, chemotherapy or radiation therapy.
Twelve patients received adjuvant endocrine therapy, 11 with tamoxifen and one with an aromatase inhibitor.
These women will receive adjuvant endocrine therapy, and rates of locoregional recurrence, metastasis, and overall survival as well as type of salvage therapy will be tracked, with follow-up planned for 10 years and the primary endpoint being 5-year locoregional recurrence-free survival.
Javid, "Adjuvant endocrine therapy in patients with ductal carcinoma in situ: a population-based retrospective analysis from 2005 to 2012 in the national cancer data base," Annals of Surgical Oncology, vol.
Patients are treated by adjuvant anthracycline-based chemotherapy; additional treatment with adjuvant endocrine therapy will be administered when tumor cells are ER/PR+.
To the Editor: Letrozole, a third-generation aromatase inhibitor (AI), is a relatively newer class of endocrine agents used in hormone-receptor-positive breast cancer.[sup][1] Vascular thrombotic events, such as acute myocardial infarction and acute cerebral infarction, in patients with breast cancer after initiation of letrozole therapy have been documented in the literature.[sup][2],[3] However, the impact of this adjuvant endocrine therapy on increasing the risk of developing vascular thrombotic events has been a controversial issue.